(Q24201783)

21 October 2023

2

Ivan Solà

Ivan

Solà

1 reference

21 October 2023

Dimitrios Lathyris

3

Dimitrios

Lathyris

1 reference

23440809

21 October 2023

Despoina-Elvira Karakitsiou

series ordinal

4

author given names

Despoina-Elvira

author last names

Karakitsiou

1 reference

23440809

21 October 2023

Daniel Simancas-Racines

series ordinal

5

author given names

Daniel

author last names

Simancas-Racines

1 reference

23440809

Cochrane Database of Systematic Reviews

21 October 2023

publication date

31 January 2013

0 references

published in

0 references

cites work

High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Secondary prevention with folic acid: effects on clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Secondary prevention with folic acid: results of the Goes extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine lowering with folic acid and B vitamins in vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine lowering and cardiovascular events after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

B vitamin and/or ω-3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega-3 fatty acids (SU.FOL.OM3) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

The SU.FOL.OM3 Study: a secondary prevention trial testing the impact of supplementation with folate and B-vitamins and/or Omega-3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Vitamin Intervention For Stroke Prevention trial: an efficacy analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized subs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Effect of long-term homocysteine reduction with B vitamins on arterial wall inflammation assessed by fluorodeoxyglucose positron emission tomography: a randomised double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

The role of vitamin B in stroke prevention: a journey from observational studies to clinical trials and critique of the VITAmins TO Prevent Stroke (VITATOPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

VITATOPS, the VITAmins TO prevent stroke trial: rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Effect of homocysteine-lowering B vitamin treatment on angiographic progression of coronary artery disease: a Western Norway B Vitamin Intervention Trial (WENBIT) substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Dietary folate and vitamin b6 and B12 intake in relation to mortality from cardiovascular diseases: Japan collaborative cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Effect of physiological doses of oral vitamin B12 on plasma homocysteine: a randomized, placebo-controlled, double-blind trial in India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Cancer incidence and mortality after treatment with folic acid and vitamin B12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Folate therapy and in-stent restenosis after coronary stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Efficacy of homocysteine-lowering therapy with folic Acid in stroke prevention: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Impact of homocysteine-lowering vitamin therapy on long-term outcome of patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Effect of homocysteine interventions on the risk of cardiocerebrovascular events: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine, vitamin B12 and folate levels in Iranian patients with ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

The controversial role of B-vitamins in cardiovascular risk: An update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

The effect of folic acid supplementation on carotid intima-media thickness in patients with cardiovascular risk: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Efficacy of folic acid supplementation in stroke prevention: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine and cardiovascular disease: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Effect of folic acid supplementation on cardiovascular outcomes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

GRADE guidelines: 3. Rating the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Genetics of homocysteine metabolism and associated disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine metabolism, hyperhomocysteinaemia and vascular disease: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Effects of B-vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Folic acid food fortification-its history, effect, concerns, and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Vitamin B(6) salvage enzymes: mechanism, structure and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Cardiovascular disease epidemiology: a journey from the past into the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Physiological and molecular aspects of cobalamin transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Structural modifications of HDL and functional consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine: overview of biochemistry, molecular biology, and role in disease processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Vitamin B6 and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Association between homocysteine, vitamin B(6) concentrations and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine: role and implications in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

GRADE guidelines: 2. Framing the question and deciding on important outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

GRADE guidelines: 9. Rating up the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

GRADE guidelines: 8. Rating the quality of evidence--indirectness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

GRADE guidelines: 7. Rating the quality of evidence--inconsistency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

GRADE guidelines 6. Rating the quality of evidence—imprecision

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

GRADE guidelines: 5. Rating the quality of evidence--publication bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine level and coronary heart disease incidence: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Meta-research: The art of getting it wrong

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Molecular targeting by homocysteine: a mechanism for vascular pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine targeting of plasma proteins in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Molecular basis of homocysteine toxicity in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

The impact of prevention on reducing the burden of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Biochemistry of B12-cofactors in human metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

The treatment of hyperhomocysteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Hyperhomocysteinemia and arteriosclerosis: historical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Genetic aspects of folate metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine and its disulfide derivatives: a suggested consensus terminology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Pyridoxal phosphate: biosynthesis and catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine and lipids: S-adenosyl methionine as a key intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Human folate bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Mechanisms of homocysteine toxicity in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Public health significance of elevated homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Low vitamin B6 and folic acid levels are associated with retinal vein occlusion independently of homocysteine levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Estimating required information size by quantifying diversity in random-effects model meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Folate and vitamin B-12 biomarkers in NHANES: history of their measurement and use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Contributions of hyperhomocysteinemia to atherosclerosis: Causal relationship and potential mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Homocysteine lowering interventions for preventing cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

Vitamin status and intake as primary determinants of homocysteinemia in an elderly population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021

Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021

Effect of folate supplementation on serum homocysteine and plasma total antioxidant capacity in hypercholesterolemic adults under lovastatin treatment: a double-blind randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

1 reference

7 January 2021

Homocysteine as a new risk factor for cardiovascular events in heart failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021

GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021

Homocysteine-lowering vitamins do not lower plasma S-adenosylhomocysteine in older people with elevated homocysteine concentrations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021

Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021

The many facets of hyperhomocysteinemia: studies from the Framingham cohorts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021

Control of baseline cardiovascular risk factors in the SU-FOL-OM3 study cohort: does the localization of the arterial event matter?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021

Coronary blood flow in patients with stable coronary artery disease treated long term with folic acid and vitamin B12.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021

Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021

Enhanced cellular adenosine uptake limits adenosine receptor stimulation in patients with hyperhomocysteinemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021

Folic acid-based intervention in non-ST elevation acute coronary syndromes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021

National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021

Effect of homocysteine-lowering treatment with folic Acid and B vitamins on risk of type 2 diabetes in women: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021

Effect of 3 y of folic acid supplementation on the progression of carotid intima-media thickness and carotid arterial stiffness in older adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021

A dose-finding trial of the effect of long-term folic acid intervention: implications for food fortification policy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006612.PUB3

7 January 2021